Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Kosan Biosciences has announced that the FDA has granted the company’s anticancer compound 17-allylamino-17-demethoxy-geldanamycin (17-AAG), an analog of the polyketide geldanamycin, orphan drug status for the treatment of multiple myeloma.

In the Pipleline